These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17450764)

  • 1. [Guidelines for prescribing and monitoring biologic therapies in juvenile idiopathic arthritis].
    Santos MJ; Fonseca JE; Canhão H; Conde M; José Vieira M; Costa L; Costa M; Salgado M; Melo Gomes JA;
    Acta Reumatol Port; 2007; 32(1):43-7. PubMed ID: 17450764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
    Ruperto N; Murray KJ; Gerloni V; Wulffraat N; de Oliveira SK; Falcini F; Dolezalova P; Alessio M; Burgos-Vargas R; Corona F; Vesely R; Foster H; Davidson J; Zulian F; Asplin L; Baildam E; Consuegra JG; Ozdogan H; Saurenmann R; Joos R; Pistorio A; Woo P; Martini A;
    Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K; Ortiz-Alvarez O; Cabral DA; Tucker LB; Petty RE; Malleson PN
    J Rheumatol; 2004 Jan; 31(1):179-82. PubMed ID: 14705239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis.
    Ortiz-Alvarez O; Morishita K; Avery G; Green J; Petty RE; Tucker LB; Malleson PN; Cabral DA
    J Rheumatol; 2004 Dec; 31(12):2501-6. PubMed ID: 15570658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
    Ruperto N; Lovell DJ; Cuttica R; Wilkinson N; Woo P; Espada G; Wouters C; Silverman ED; Balogh Z; Henrickson M; Apaz MT; Baildam E; Fasth A; Gerloni V; Lahdenne P; Prieur AM; Ravelli A; Saurenmann RK; Gamir ML; Wulffraat N; Marodi L; Petty RE; Joos R; Zulian F; McCurdy D; Myones BL; Nagy K; Reuman P; Szer I; Travers S; Beutler A; Keenan G; Clark J; Visvanathan S; Fasanmade A; Raychaudhuri A; Mendelsohn A; Martini A; Giannini EH; ;
    Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence-based use of methotrexate in children with rheumatic disorders. Consensus statement of the Working Group for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and the Working Group Pediatric Rheumatology Austria].
    Niehues T; Horneff G; Michels H; Sailer Höck M; Schuchmann L
    Z Rheumatol; 2004 Apr; 63(2):147-58. PubMed ID: 15112095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals.
    Beresford MW; Baildam EM
    Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of etanercept in the treatment of juvenile idiopathic arthritis].
    de Inocencio Arocena J; Merino Muñoz R; Alvarez Madrid C; García-Consuegra Molina J
    An Pediatr (Barc); 2009 Apr; 70(4):354-61. PubMed ID: 19324597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease.
    Ringold S; Bittner R; Neogi T; Wallace CA; Singer NG
    Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1095-102. PubMed ID: 20506561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.
    Céspedes-Cruz A; Gutiérrez-Suárez R; Pistorio A; Ravelli A; Loy A; Murray KJ; Gerloni V; Wulffraat N; Oliveira S; Walsh J; Penades IC; Alpigiani MG; Lahdenne P; Saad-Magalhães C; Cortis E; Lepore L; Kimura Y; Wouters C; Martini A; Ruperto N;
    Ann Rheum Dis; 2008 Mar; 67(3):309-14. PubMed ID: 17875547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
    Borte S; Liebert UG; Borte M; Sack U
    Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile idiopathic arthritis--current and future therapies.
    Kahn P
    Bull NYU Hosp Jt Dis; 2009; 67(3):291-302. PubMed ID: 19852753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.
    Bartoli M; Tarò M; Magni-Manzoni S; Pistorio A; Traverso F; Viola S; Magnani A; Gasparini C; Martini A; Ravelli A
    Ann Rheum Dis; 2008 Mar; 67(3):370-4. PubMed ID: 17660217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New advances in the management of juvenile idiopathic arthritis--1: non-biological therapy.
    Beresford MW; Baildam EM
    Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):144-50. PubMed ID: 19770494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
    Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.
    Albers HM; Wessels JA; van der Straaten RJ; Brinkman DM; Suijlekom-Smit LW; Kamphuis SS; Girschick HJ; Wouters C; Schilham MW; le Cessie S; Huizinga TW; Ten Cate R; Guchelaar HJ
    Arthritis Rheum; 2009 Jan; 61(1):46-51. PubMed ID: 19116975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.